Beinaglutide 产品活性：Beinaglutide 是一种人 GLP-1 多肽，与人 GLP-1(7-36) 具有几乎 100% 的同源性。Beinaglutide 在血糖控制、抑制食物摄入和胃排空和促进体重减轻方面表现出依赖于剂量的作用。Beinaglutide 具有研究超重/肥胖和非酒精性脂肪性肝炎 (NASH) 的潜力。 产品来源： https://www.medchemexpress.cn/beinaglutide.html 研究领域：GPCR/G Protein 作用靶点：GCGR In Vitro: Beinaglutide (100 nM; 48 h) increases the expression of phosphorylation of Akt in the adipocytes that were potentiated insulin-stimulated. In Vivo: Beinaglutide (0.6, 1.2, 2.4 mg/kg; s.c.; three times per day for 7 consecutive days) shows the ability of glycemic contro, inhibits food intake and weight loss in mouse.? Beinaglutide (150 μg/kg; s.c.; daily for 6 weeks) increases insulin sensitivity of adipocytes. 相关产品：Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Peptide Library | Semaglutide | Exendin-4 | Liraglutide | Glucagon (1-29), bovine, human | Exendin(9-39) amide | Retatrutide | Orforglipron | GLP-1(7-37) | GLP-1(7-36), amide acetate | MK 0893 | Adomeglivant | BETP | Cotadutide acetate | GLP-1R Antagonist 1 | Danuglipron | GLP-1(9-36)amide | GLP-2(1-33)(human) | Oxyntomodulin (bovine, porcine) | Lixisenatide | Lotiglipron | Survodutide | NNC-0640 | Mazdutide | GLP-1R agonist 2 | LGD-6972 | PF-06291874 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。